5,000 Xarelto Lawsuits And Controversial FDA Approval Discussed In Business Insider

March 08, 2016 – – BloodThinnerHelp.com reports on a recent Business Insider article which discusses Xarelto lawsuits and controversies surrounding manufacturing pharmaceutical companies Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals. The article notes that the recent controversy was stirred after a document was released alleging that the two pharmaceutical corporations may have chosen to mislead a leading medical journal about facts surrounding Xarelto by purposefully failing to mention certain important data collected regarding the blood-thinning drug.

Xarelto is a new-generation blood thinner which is used to treat patients recovering from knee and hip replacement surgeries, those with deep vein thrombosis or pulmonary embolism, and those with atrial fibrillation. It is designed to prevent the occurrence of blood clots and strokes in these patients. In the year 2015 alone, according to the Business Insider article, Xarelto made an estimated $1.8 billion in U.S. sales. Despite this obvious popularity, however, the drug has been the topic of a surging number of lawsuits, which, according to Business Insider, now number over 5,000, and 500 of which discuss patient fatalities.

The Business Insider article, however, delves deeper into the controversy than many of the plaintiffs involved in these lawsuits have been able to. It notes that, “The New York Times’ Katie Thomas found in a footnote in a federal legal briefing that there might be some evidence that the drug’s developers, Johnson & Johnson and Bayer, may have left out some critical data when a peer reviewer (a researcher who is independent of the study who goes through and vets the findings) at the New England Journal of Medicine asked for it.”

These latest controversies follow recent concerns regarding a clinical trial of the drug; and that trial’s effectiveness after it was noted that a recalled device may have been used and that results may have been altered in favor of the blood thinner.

At this time, as controversies continue to mount, it has been reported that both the U.S. Food and Drug Administration and the European Medicine Agency are further investigating these issues, and looking into whether the faulty blood-testing device discussed may have led to the drug’s premature FDA approval.

Attorney Joseph Osborne is hoping that as further investigations take place, those affected will have additional time to evaluate their legal rights and determine their legal options. Patients who used Xarelto and suffered from health problems that they believe the drug caused may qualify for substantial compensation. To help those deserving pursue justice with more ease, Attorney Osborne is currently offering free legal consultations for affected parties.

To request additional Xarelto lawsuit information, or to ask questions at any time, please contact Attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008559